McKay Heather, Derome Francine, Haq M Anwar, Whittaker Susan, Arnold Emmy, Adam Frédéric, Heddle Nancy M, Rivard Georges E, Hayward Catherine P M
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Blood. 2004 Jul 1;104(1):159-65. doi: 10.1182/blood-2003-11-4077. Epub 2004 Mar 16.
Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder associated with increased urokinase-type plasminogen activator in platelets and alpha-granule protein degradation. To determine bleeding risks and common manifestations of QPD, a history questionnaire was developed and administered to 127 relatives in a family with QPD. Data entry was done blinded to affected and unaffected status, determined by assays for platelet urokinase-type plasminogen activator (u-PA) and fibrinogen degradation. Odds ratios (ORs), with 95% confidence intervals (CIs), were determined for items queried. Summative bleeding scores for each individual were calculated using items with OR more than 1. Mean ages (34 years; range, 1-89 years) were similar for affected (n = 23) and unaffected (n = 104) family members. Affected individuals had higher mean bleeding scores (P <.0001) and a much higher likelihood (OR > 20) of having bleeding that led to lifestyle changes, bruises that spread lower or as large or larger than an orange or both, joint bleeds, bleeding longer than 24 hours after dental extractions or deep cuts, and received or been recommended other treatments (fibrinolytic inhibitors) for bleeding. Individuals with QPD and exposure(s) to hemostatic challenges had experienced excessive bleeding only when fibrinolytic inhibitors had not been used. These data illustrate that QPD is associated with increased risks of bleeding that can be modified by fibrinolytic inhibitors.
魁北克血小板疾病(QPD)是一种常染色体显性遗传性出血性疾病,与血小板中尿激酶型纤溶酶原激活物增加及α-颗粒蛋白降解有关。为了确定QPD的出血风险和常见表现,我们编制了一份病史问卷,并对一个患有QPD的家族中的127名亲属进行了调查。数据录入时对受影响和未受影响的状态设盲,状态通过血小板尿激酶型纤溶酶原激活物(u-PA)和纤维蛋白原降解检测来确定。对所询问的项目确定比值比(OR)及95%置信区间(CI)。使用OR大于1的项目计算每个个体的累积出血评分。受影响(n = 23)和未受影响(n = 104)的家庭成员平均年龄相似(34岁;范围1 - 89岁)。受影响个体的平均出血评分更高(P <.0001),并且因出血导致生活方式改变、瘀斑扩散至更低部位或瘀斑大小大于或等于橙子大小、关节出血、拔牙或深部切割后出血超过24小时以及接受或被建议使用其他治疗(纤溶抑制剂)来治疗出血的可能性要高得多(OR > 20)。患有QPD且面临止血挑战的个体仅在未使用纤溶抑制剂时才会出现过度出血。这些数据表明,QPD与出血风险增加有关,而纤溶抑制剂可改变这种风险。